In 2-year data from two phase 3 trials and their open-label extension in axial spondyloarthritis (586 patients; 456 completed week 104), bimekizumab-treated patients reported sustained falls from baseline in spinal pain (−4.3), morning stiffness (−4.3) and BASFI (−2.9).
RCTn = 586
Marzo-Ortega et al. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies